A pharmacological inhibitor of SGLT2 (sodium-glucose co-transporters inhibitor) has been evaluated as a useful drug for the treatment of obesity, diabetes, and hypertension with no significant toxic effects (9). The gene discussed is SLC5A2; the disease is obesity disorder.